EP3697398A1 — Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
Assigned to Aragon Pharmaceuticals Inc · Expires 2020-08-26 · 6y expired
What this patent protects
The invention provides methods of treating non-metastatic castration-resistant prostate cancer with a licensed drug product comprising apalutamide, enzalutamide, or darolutamide. The present invention also relates to medicinal products containing apalutamide, enzalutamide or daro…
USPTO Abstract
The invention provides methods of treating non-metastatic castration-resistant prostate cancer with a licensed drug product comprising apalutamide, enzalutamide, or darolutamide. The present invention also relates to medicinal products containing apalutamide, enzalutamide or darolutamide, as well as methods of selling or offering for sale an anti-androgen drug product.
Drugs covered by this patent
- Erleada (apalutamide) · Johnson & Johnson
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.